Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel

Print E-mail
Monday, 01 June 2015 14:36

Haifa, Israel, June 1, 2015 -- Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, today announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and viagra next day delivery disease treatment in China, South Korea, Mexico, Russia, and Israel.

Read more...
 

Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel

Print E-mail
Monday, 01 June 2015 14:36

Haifa, Israel, June 1, 2015 -- Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, today announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and disease treatment in China, South Korea, Mexico, Russia, and Israel.

Read more...
 

Actinium’s Actimab-A High Response Rates Presented at 2015 ASCO Annual Meeting Clinical Advisory Board Chairman Dr. Joseph Jurcic Presents Data from Ongoing Actimab-A Phase I/II Clinical Trial

Print E-mail
Friday, 29 May 2015 18:34

NEW YORK, NY –- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced its poster and medexpressrx abstract at ASCO 2015, the 51st Annual Meeting of American Society of Clinical Oncology, held in Chicago on May 29 – June 2. Data will be presented from the Company’s ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients.

Read more...
 

Provectus’ Abstract on Liver Cancer Accepted for Poster Presentation at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

Print E-mail
Thursday, 28 May 2015 19:27

KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), a clinical-stage oncology and buy brand propecia online dermatology biopharmaceutical company (“Provectus” or the “Company”), announced today that the organizing committee of the 6th Asia-Pacific Primary Liver Cancer Expert Meeting has accepted the Company’s abstract "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and propecia blogs Cancer Metastatic to the Liver", for a poster presentation.

Read more...
 

Provectus Biopharmaceuticals’s Abstract Accepted for Poster Presentation at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Print E-mail
Wednesday, 27 May 2015 18:50

KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), today announced that the presentation committee of the 5th European Post-Chicago Melanoma / Skin Cancer Meeting has accepted its abstract titled “Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma.”

Read more...
 

PlasmaTech Biopharmaceuticals Announces Orphan Drug and viagra for sale Rare Pediatric Disease Designations from FDA

Print E-mail
Wednesday, 20 May 2015 14:03

NEW YORK, NY--PlasmaTech Biopharmaceuticals, Inc. (PTBI), a biopharmaceutical company focused on gene therapy and priligy review plasma-based products for severe and buy real cialis life- threatening rare diseases announced today that the U.S. Food and viagra pfizer Drug Administration (FDA) had granted both Orphan Drug Designation and brand viagra Rare Pediatric Disease Designation for both of PlasmaTech Biopharmaceuticals' lead product candidates for the treatment of Sanfilippo Syndromes A and B.

Read more...
 

Significant Progress for Pluristem: PLX Cells Were Selected for European Medicines Agency's Adaptive Pathways Pilot Project

Print E-mail
Monday, 18 May 2015 14:33

HAIFA, Israel--Pluristem Therapeutics Inc. (PSTI), a leading developer of placenta-based cell therapy products, today announced a significant advancement to its clinical development plan: the PLX cell program in critical limb ischemia has been selected for the European Medicines Agency's Adaptive Pathways pilot project.

Read more...
 

Pluristem’s PLX Cells One Step Closer to Entering Japan’s Accelerated Pathway for Regenerative Medicine

Print E-mail
Wednesday, 13 May 2015 07:38

HAIFA, ISRAEL, May 13, 2015 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced that Japan’s Pharmaceuticals and generic cialis Medical Devices Agency (PMDA) agreed with the proposed quality and purchase generic cialis online large-scale manufacturing methods for PLX-PAD cells for use in clinical trials.

Read more...
 

PlasmaTech Biopharmaceuticals Announces Appointment of Todd Wider, MD to Board of Director

Print E-mail
Tuesday, 12 May 2015 18:18

PlasmaTech Biopharmaceuticals, Inc. ("PlasmaTech" or the "Company") (NASDAQ: PTBI), a biopharmaceutical company focused on advancing cell therapy and gene therapy for rare diseases, announced today that Todd Wider, MD has been elected to the Company's Board of Directors.

Read more...
 

Lubrizol to Showcase Expanded Global Solutions at IATI Biomed 2015

Print E-mail
Tuesday, 12 May 2015 00:43

CLEVELAND, May 12, 2015 - The Lubrizol Corporation announces that its LifeSciences business (Booth 66) will showcase its total solutions capabilities, including those from the acquisition of Vesta and buy cialis without prescription recent alliance with Particle Sciences at IATI Biomed 2015 in Tel Aviv, Israel.
Read more...
 
<< Start < Prev 1 3 4 5 6 > End >>

Page 1 of 6

Newsletter

BioMedReports An Undervalued Biotech Is Testing the Cure for Cancer Now, and Chen Lin Wants In: Chen Lin produces a monthly ... http://t.co/xbROAbBvKa
5hreplyretweetfavorite
BioMedReports MannKind's inhaled insulin drug proves hard for diabetics to get... http://t.co/t6eDqtz3Bu
9hreplyretweetfavorite
BioMedReports Insys Therapeutics Inc (NASDAQ:INSY) Submits NDA for Dronabinol Oral Solution: Insys Therapeutics Inc (NASDAQ:... http://t.co/TO8pAFs4ox
9hreplyretweetfavorite